JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Amgen’s Product Performance in Q2 2018
    Market Realist3 hours ago

    Amgen’s Product Performance in Q2 2018

    Amgen’s (AMGN) product portfolio includes the blockbuster drugs Prolia, Enbrel, Neulasta, Xgeva, Aranesp, Sensipar/Mimpara, Kyprolis, and Epogen. Blockbuster drug Neulasta (pegfilgrastim) reported a 1% rise in revenue to $1.10 billion during the second quarter compared to ~$1.09 billion in the second quarter of 2017.

  • St. Charles County lawsuit accuses drug companies, distributors of worsening opioid epidemic
    American City Business Journals5 hours ago

    St. Charles County lawsuit accuses drug companies, distributors of worsening opioid epidemic

    St. Charles County has filed a lawsuit against a group of pharmaceutical manufacturers and drug distributors, accusing them of "aggressive and fraudulent marketing" of prescription opioid painkillers that has led to a drug abuse epidemic.

  • Benzinga6 hours ago

    5 Execs Talk Business Models At Cannabis Capital Conference

    Five cannabis industry executives laid out their business models and viewpoints Friday at the Benzinga Cannabis Capital Conference in Toronto. Zoning laws and regulations are some of the biggest challenges for cannabis dispensaries, Vahan Ajamian, MedMen's (OTC: MMNFF) managing director of analyst relations, said during the conference.

  • Drugmakers Extend Summer Rally as Markets Regain Footing
    Bloomberg7 hours ago

    Drugmakers Extend Summer Rally as Markets Regain Footing

    Major pharmaceutical companies are partying like it’s 2001. U.S. drugmakers including Pfizer Inc., Eli Lilly & Co., and Merck & Co. are seeing their share prices balloon to the highest levels in more than 16 years as investors rotate in after second-quarter results proved stronger than expected. Impressive earnings paired with waning concerns about potential Trump administration actions on drug pricing could be helping to draw generalist investors in a bit of a “catch up trade,” according to Credit Suisse analyst Vamil Divan.

  • What You Must Know About Johnson & Johnson’s (NYSE:JNJ) Financial Strength
    Simply Wall St.10 hours ago

    What You Must Know About Johnson & Johnson’s (NYSE:JNJ) Financial Strength

    The size of Johnson & Johnson (NYSE:JNJ), a US$360.75b large-cap, often attracts investors seeking a reliable investment in the stock market. Big corporations are much sought after by risk-averse investorsRead More...

  • Array BioPharma’s Immuno-Oncology Collaborations: Trial Update
    Market Realist10 hours ago

    Array BioPharma’s Immuno-Oncology Collaborations: Trial Update

    Array BioPharma (ARRY) is developing a number of combination therapies with its investigational MEK inhibitor binimetinib with PD-1/PD-L1 checkpoint inhibitors. The company is conducting the trials in collaboration with Bristol-Myers Squibb (BMY), Pfizer (PFE), and Merck (MRK). During its fourth-quarter and full-fiscal 2018 earnings release on August 14, Array Biopharma provided updates on these trials.

  • Allergan’s International Business Segment in Q2 2018
    Market Realist10 hours ago

    Allergan’s International Business Segment in Q2 2018

    Allergan’s (AGN) International Business segment includes the revenues from both its specialized therapeutics portfolio and its general products portfolio from outside US markets.

  • Mylan Cuts Its Fiscal 2018 Guidance, Citing US Market Challenges
    Market Realist10 hours ago

    Mylan Cuts Its Fiscal 2018 Guidance, Citing US Market Challenges

    Mylan (MYL) made a downward revision to its fiscal 2018 guidance during its second-quarter earnings release on August 8. A major factor driving down the company’s performance was lower North America sales due to volume declines in the company’s existing products. Due to the impact of “turbulence in the U.S. and the disturbing trends regarding access to complex products,” Mylan lowered its fiscal 2018 guidance during its second-quarter earnings release on August 8.

  • 5 Hot Stocks in the Dow ETF Last Week
    Zacks10 hours ago

    5 Hot Stocks in the Dow ETF Last Week

    Dow Jones closed at its highest level since February, We have highlighted the five best performing stocks of last week in its ETF.

  • Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business
    PR Newswire10 hours ago

    Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business

    Mathai Mammen, Global Head, Janssen Research & Development and Lesley Fishman, Senior Director Investor Relations will host the call. The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

  • Business Wire10 hours ago

    Pfizer Invites Public to View and Listen to Webcast of August 27 Conference Call with Analysts and Investors to Review Tafamidis Data Presentation at ESC Congress 2018

    Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Monday, August 27, 2018 at 9:00 a.m. EDT. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today. Visitors to www.pfizer.com/investors will be able to view and listen to an archived copy of the webcast of the conference call.

  • Mylan Has a Strong Balance Sheet despite Weak Q2 Performance
    Market Realist11 hours ago

    Mylan Has a Strong Balance Sheet despite Weak Q2 Performance

    Mylan (MYL) ended the second quarter with cash and cash equivalents of $330.2 million. This compared to the net cash provided by operating activities of $1.02 billion available to the company by the end of the fiscal second quarter of 2017. For the six months ended June 30, Mylan’s adjusted free cash flows were $1.3 billion, up ~22% YoY (year-over-year).

  • 3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro
    Motley Fool12 hours ago

    3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro

    The company gives its thoughts on the drug's label, market size, and price.

  • MARKETS: Stocks rally but face headline risk in both directions
    Yahoo Finance Video3 hours ago

    MARKETS: Stocks rally but face headline risk in both directions

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.